Epidermal growth factor (EGF) has a profound effect on the differentiation of specific cells in vivo and is a potent mitogenic factor for a variety of cultured cells. The EGF precursor is believed to exist as a membrane-bound molecule which is proteolytically cleaved to generate the 53-amino acid peptide hormone that stimulates cells to divide. EGF exerts its actions by binding to the EGFR, a 170 kDa protein.

Epidermal growth factor (EGF) is a key growth factor regulating cell survival. Through its binding to cell surface receptors, EGF activates an extensive network of signal transduction pathways that include activation of the PI3K/AKT, RAS/ERK and JAK/STAT pathways. Because of its key role in driving the proliferation of cells, EGFR is a target of several anti-cancer drugs currently in development.

Granulocyte Colony Stimulating Factor(G-CSF) a cytokine that controls the production, differentiation, and function of granulocytes. It is a potent stimulator of bone marrow cells especially those of neutrophil lineage. In addition, G-CSF can enhance the survival and activate the immunological functions of mature neutrophils.
Recombinant human G-CSF has been developed by pharmaceutical companies, and since the late 1980's, multiple clinical trials have explored its efficacy in a variety of medical conditions.

Streptokinase is an extracellular metallo-enzyme produced by beta-haemolytic streptococcus and is used as an effective and cheap clot-dissolving medication in some cases of myocardial infarction (heart attack) and pulmonary embolism. It belongs to a group of medications known as fibrinolytics, and works by activating plasminogen through cleavage to produce plasmin. The half life of streptokinase is approximately 20 minutes (quoted in SPC).